XNAS · Health Information Services
Last stored close · Nov 12, 2026
Close · Nov 12, 2026
$59.92+1.39%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
38/100
Weak
Score components
TickerWhale View
Heartflow scores 38 out of 100 overall, which we rate weak. Technical is its strongest area and Quality & growth its weakest.
What helps
- Technical
- Risk
- Sentiment Signal
What to watch
- Quality & growth
- Valuation
Quality & growth
30%2Weak
- Revenue growth n/a
- EPS growth n/a
Valuation
25%2Weak
- P/E -43.7
- EV/Sales 24.2
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#123 / 139sector rank by TickerWhale Score
TickerWhale Score 38 vs sector average 54.3 (-16.3)
Gross margin (industry)Top 27%
Return on equity (industry)Top 91%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
87/100Strong vs universe
Ranks 87th of 100 covered names on our technical composite — the composite itself scores 76/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
5 buy · 2 sell · 1 neutral of 8 votes
TickerWhale rates HTFL's technical setup strong — 87th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+70.6%
- vs 50-day+15.4%
Momentum
Mixed
- RSI (14)62 · neutral
- Stochasticsell
- CCIbuy
- Williams %Rsell
Trend
Constructive
- ADX (14) trend strength21· trending
- MACD (12,26,9)buy(histogram 0.025)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 4 buy · 2 sell · 1 neutral.
Result — 5 buy vs 2 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-12 · revised_latestValuation multiples
- P/E (TTM)-43.7 · TTM loss
- P/S (TTM)24.4
- P/B18.5
- EV/EBITDA—
- EV/Sales24.2
- PEG—
Profitability & returns
- Gross margin80.1%
- Net margin-55.8%
- ROE-41.9%
- Debt/Equity0.00
Growth
- Revenue growth (YoY)—
- EPS growth (YoY)—
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $5.2B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: INSW →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HTFLCurrentHeartflow | 38 | 76 | -43.7 | — | 18.5 | 24.2 | $59.92 | +1.39% | — | ||
| EXELExelixis | 81 | 85 | 21.1 | — | 9.8 | 7.3 | $69.84 | -1.22% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 80 | 99.5 | — | 12.3 | 9.4 | $96.28 | +0.54% | +58.9% | ||
| TGTXTG Therapeutics | 78 | 85 | 23.0 | — | 16.8 | 13.0 | $64.56 | -1.82% | +76.1% | ||
| INCYIncyte | 77 | 70 | 15.7 | — | 4.0 | 3.7 | $121.70 | -0.47% | +26.9% | ||
| THCTenet Healthcare | 75 | 78 | 10.7 | — | 5.2 | 1.6 | $286.86 | -2.09% | +7.5% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.